Abstract

<div>Abstract<p><b>Purpose:</b> Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors.</p><p><b>Experimental Design:</b> High-throughput siRNA screening technology was used to systematically assess all genes within regions commonly amplified in high-grade serous and endometrioid cancer. We describe the results from a boutique siRNA screen of 272 genes in a panel of 18 ovarian cell lines. Hits identified by the functional viability screen were further interrogated in primary tumor cohorts to determine the clinical outcomes associated with amplification and gene overexpression.</p><p><b>Results:</b> We identified a number of genes as critical for cellular viability when amplified, including <i>URI1</i>, <i>PAK4</i>, <i>GAB2</i>, and <i>DYRK1B</i>. Integration of primary tumor gene expression and outcome data provided further evidence for the therapeutic use of such genes, particularly <i>URI1</i> and <i>GAB2</i>, which were significantly associated with survival in 2 independent tumor cohorts.</p><p><b>Conclusion:</b> By taking this integrative approach to target discovery, we have streamlined the translation of high-resolution genomic data into preclinical <i>in vitro</i> studies, resulting in the identification of a number of genes that may be specifically targeted for the treatment of advanced ovarian tumors. <i>Clin Cancer Res; 19(6); 1411–21. ©2013 AACR</i>.</p></div>

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.